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ABSTRACT
The purpose of this study is to assess innovation system performance and
identify the system-blocking mechanisms for AI healthcare technology
innovations related to the life science industry. The socio-technical
analytical framework Technological innovation systems (TIS) was used
to assess the structural and functional dynamics of AI healthcare
technology innovations related to the life science industry in West
Sweden. The case study employs a mixed-method research approach,
triangulating qualitative and quantitative data from secondary
published sources and interviews with 21 experts and 25 life science
business executives. The results reveal that innovation system
performance is primarily restricted by the system weaknesses of limited
resources and insufficient communication from leading healthcare
professionals regarding their needs for improving healthcare using AI
technology innovations. This study shows that to improve innovation
system performance, policy interventions intended to increase available
resources and to formulate vision and mission statements to improve
healthcare with AI technology innovations may be encouraged. This
study contributes to the understanding of the mechanisms and
interdependencies between system functions using the socio-technical
TIS framework in a healthcare context.
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Global societies are faced with a growing demand for high-quality healthcare as a consequence of an
aging population with an increased prevalence of patients experiencing multiple and chronic con-
ditions (Kingston et al. 2018). Increased demand in combination with cost pressures challenges
societies to deliver healthcare in a sustainable way, which cannot be managed only by increasing
resources. Quality improvement and innovation are fundamental drivers in the search for better
medical outcomes without necessarily increasing costs (Bergman et al. 2015; Liddell and Ayling
2011). A potentially powerful technique that could act as a vehicle to accelerate innovation in health-
care is artificial intelligence (AI). Healthcare is full of data-rich processes, and the accessibility to large
volumes of data, combined with the development of computer power and AI techniques, has
created tremendous opportunities (Jiang et al. 2017).
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Innovations based on AI aim to mimic human cognitive functions, and the ability of machines
using AI algorithms to understand and manipulate large datasets has advanced rapidly. One advan-
tage of applying AI in healthcare in the era of big data is that complex patterns and relationships
within the data can be discovered algorithmically without having to hire more healthcare pro-
fessionals for data analysis. AI innovations have various healthcare applications, such as predicting
mortality after cardiac surgery (Nilsson et al. 2006), as intelligent artificial prostheses (Ortiz-
Catalan, Brånemark, and Håkansson 2013), or diagnosing skin cancer as efficiently as (Esteva et al.
2017), or perhaps even better than, dermatologists (Haenssle et al. 2018). However, the digitalisation
and pace of AI adoption in the healthcare sector are low compared to other fields (Laurenza et al.
2018), and various issues on the macro, meso and micro levels have been identified (Lennon et al.
2017).
Healthcare is a complex dynamic socio-technical system combining functional elements that
evolve interdependently (Effken 2002). The socio-technical analytical framework Technological Inno-
vation Systems (TIS) has emerged as a prominent concept to assess the structure and functions that
influence innovation system performance (Bergek et al. 2008; Hekkert et al. 2007; Markard and
Truffer 2008). Previous TIS studies have taken a functional dynamics approach in various fields,
such as biorefinery development (Hellsmark et al. 2016) and off-shore wind technologies (Wieczorek
et al. 2013). To the authors’ knowledge, there are few TIS studies illuminating the healthcare sector
(Kukk, Moors, and Hekkert 2016; Larisch, Amer-Wåhlin, and Hidefjäll 2016); however, no specific
research study or review have applied the TIS framework for assessment of innovation system per-
formance related to AI healthcare technologies. Therefore, our intention is to make a contribution in
this field and explore if and how the TIS framework can be expanded into new areas, identify poss-
ible shortcomings and development areas. Thus, to contribute to a more holistic view of innovation
processes in the healthcare sector, the researchers used a TIS approach to examine the performance
and system-blocking mechanisms of AI healthcare technology innovations related to the life science
industry.
The purpose of this study is to assess innovation system performance and identify system-block-
ing mechanisms of AI healthcare technology innovations related to the life science industry. Accord-
ingly, the researchers formulated the following research questions: (1) what system strengths and
weaknesses can be identified and (2) are there implications for policy interventions for AI healthcare
technology innovations related to the life science industry?
2. Theoretical background
AI refers to machines that are able to perform tasks that would require intelligence if done by
humans. Machine learning encompasses various techniques one can use to achieve AI and refers
to computer learning without being explicitly programmed. Artificial neural networks are an
example of machine learning technology architecture, which simulates the human brain. The
human brain consists of billions of nerve cells or neurons, organised in complex interconnected net-
works allowing us to generate complex thought patterns and actions. During a lifetime, neurons
connect with other neurons, and complex patterns grow into functioning circuits. Similarly, artificial
neural networks consist of neurons or nodes, organised in different layers that can capture complex
non-linear relationships between data variables and an outcome. Deep learning is a specific subset
of artificial neural network that use multiple hidden layers to solve complex problems. For example,
convolutional deep neural networks are typically used in healthcare to analyse images, such as struc-
tured CT or MRI data. Recurrent deep neural networks are used to analyse sequential data, such as
genetic sequencing. Natural language processing (NLP) is a popular AI technique used to analyse
unstructured data, such as data from clinical examinations and electronic health record systems.
In this study, the term AI technologies refer to all generations and techniques of artificial intelligence.
Innovation systems are a group of structural components contributing to the overall function of
developing, diffusing and utilising innovations (Carlsson and Stankiewicz 1991). TIS analytical
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framework incorporates analysis of the structures and functions that influence innovation system
performance (Bergek et al. 2008; Hekkert et al. 2007; Larisch, Amer-Wåhlin, and Hidefjäll 2016;
Markard and Truffer 2008; Rickne 2000). As described in Table 1, the function knowledge develop-
ment and diffusion (F1) relates to the breadth and depth of knowledge. The function strength
can be assessed with various types of indicators, such as number of publications and qualitative
assessments by experts. The function legitimation (F2) relates to the social acceptance of the tech-
nology with relevant institutions and can be assessed with qualitative data to ascertain how legiti-
macy influences other functions and the length of time it takes from developing applications to
customer installations. The function resource mobilisation (F3) concerns the extent to which
actors are able to mobilise capital to generate and diffuse technology innovation. Guidance of
search (F4) relates to the expectations for growth potential as well as end-users’ needs relating to
the technology innovation. The function entrepreneurial experimentation (F5) refers to the exper-
imentation and testing of new technologies and applications and can be assessed with a variety
of application types. The function market formation (F6) relates to when innovations are made
widely available in markets. Indicators may include timing, size and type of market. When all func-
tions are fulfilled, a reinforcing and synergistic system can function and spread positive effects within
the innovation system and to other regions, countries or sectors. This process is sometimes referred
to as positive externalities or system-wide synergies (F7) and can be assessed by the establishment of
international standards and formal networks between actors.
3. Material and methods
The nature of the problem addressed in this research requires an in-depth exploration of experts’
thoughts to understand the processes for AI innovations related to the life science industry. A quali-
tative case study is a suitable research technique in this context, as this approach is used to explore a
phenomenon within a particular context (Eisenhardt 1989). For this case study, a mixed-methods
approach was employed and deemed to be suitable since triangulation of qualitative and quantitat-
ive data were expected to provide an in-depth understanding of the research topic (Creswell et al.
2003).
3.1. Research setting
Sweden was ranked third on the Global Innovation Index 2018 (Dutta, Lanvin, and Wunsch-Vincent
2018). Although the Swedish healthcare system ranks high on healthcare outcome measures,
Table 1. Functions of innovation systems and their indicators of strength (Bergek et al. 2008; Hekkert et al. 2007; Larisch, Amer-
Wåhlin, and Hidefjäll 2016; Markard and Truffer 2008; Rickne 2000).
System function Function description Indicators of function strength
F1 Knowledge development
and diffusion
Refers to the scientific, technological and
market knowledge base.
Number of scientific publications; assessments of
function by experts.
F2 Legitimation Relates to the social acceptance and
compliance of the technology.
How legitimacy influences demands and
behaviours; length from application
development to installation.
F3 Resource mobilisation Mobilisation of infrastructure and human
and financial resources.
Accessibility of data. Volumes of financial and
human capital.
F4 Guidance of search Influence on the direction of
development.




Refers to experimentation and testing of
new applications.
Number of different types of applications.
F6 Market formation When innovations are widely available on
the market.
Timing, size and type of markets and customers.
F7 System-wide synergies Reinforcing system where all functions
are fulfilled and spread positive effects.
Establishment of standards and formal networks
between actors.
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population health and quality of care, it ranks low on technical efficiency (Anell, Glenngård, and
Merkur 2012; Tchouaket et al. 2012). West Sweden is a key region for life science, constituting
approximately 25% of the total national population (www.scb.se). West Sweden was chosen as
the empirical setting due to the researchers’ access to data, and in this study, the structural com-
ponents refer to actors, networks and institutions relating to AI healthcare technology innovations
from a life science industry perspective. The life science industry consists of companies dedicated to
developing, producing and distributing healthcare technologies such as pharmaceuticals, medical
devices and equipment. In this study, the researchers categorised AI healthcare technology inno-
vations based on end-user applications, as described in Table 2.
3.2. Data collection and analysis
Data collection was based on qualitative interviews and secondary data from official and publicly
available documents. The interviews were divided into three phases to (1) explore the field, (2)
collect empirical evidence and (3) examine and explore experts’ experiences.
3.2.1. Phase I – in-depth interviews
In-depth interviews with eight stakeholders were conducted to inductively explore the field and
gather more information on structural components and perceived weaknesses and strengths. An
interview guide with open-ended questions was developed to allow participants to express their
viewpoints and experiences (Flick 2018). Sample selection used the snowball sampling technique
(Flick 2018). The interviews included one local policy-maker, three researchers, one medical
doctor, two industry associates and one financial investor. Each interview lasted approximately 30
−60 min. Interview notes were transcribed and analysed using the qualitative content analysis soft-
ware program NVivo.
3.2.2. Phase II – phone surveys
Phone interviews were conducted to collect empirical evidence from life science companies that
have developed, or are in the process of developing, AI innovations. To identify companies, second-
ary data and participants in phase I was consulted. Supplementary data, including revenues and
number of employees, were collected through published data sources (www.allabolag.se). Thirty
companies were identified and contacted by phone or email. Five companies did not yet consider
applying AI technologies and were excluded from the research. Phone interviews were conducted
during which each company representative was asked to define the company’s AI initiatives
based on end-user application. On six occasions, more than one end-user application was
applied, and the researchers decided to include all applications for further analysis. Three appli-
cations were specifically used for pharmaceutical development by the industry and were excluded
from analysing commercially deployed innovations utilised in healthcare. The researchers cate-
gorised captured data into innovation types (OECD 2018). Each company representative was
asked to rank the level of adoption, as described in Table 3. Interviews lasted 20−30 min.
Table 2. Categorisation of AI healthcare technology innovations based on end-user applications.
End-user application Example
Pharmaceutical development Drug discovery and drug design.
Medical device therapy Artificial body parts translate signals from the brain.
Diagnostics Tools for detecting correlations between symptoms and diseases.
Education Medical simulators are used for the training of healthcare professionals.
Decision support Advanced image analysis is used to make better decisions.
Patient support Digital apps are used by patients to increase compliance.
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3.2.3. Phase III – semi-structured expert interviews
Semi-structured expert interviews were conducted with open-ended questions to allow for further
exploration of the phenomena (Flick 2018). An interview guide was created based on the theoretical
framework and knowledge about the phenomena gathered in phase I. In the event company repre-
sentatives in phase II ranked the adoption as five or above, they were asked to appoint AI experts
within their organisations. An expert was defined as an individual having technical, process-oriented
and interpretive knowledge of AI technologies gained from research, development, computer
science, IT, marketing or business development. All experts who were contacted agreed to partici-
pate in the study. A total of 13 expert interviews, each lasting approximately 60 min were conducted,
as categorised in Table 4. Interview notes were transcribed and coded according to themes that cor-
responded to the research questions using the qualitative content analysis software program NVivo.
4. Results and analysis
4.1. Structural components
The healthcare sectoral map illustrated in Figure 1 was developed based on information provided
by study participants and secondary data from published sources and includes key actors
classified into academic, market and governance spheres on the vertical axis and along the
value chain on the horizontal axis. Chalmers University of Technology, Gothenburg University
and regional universities and colleges were identified as central actors within the academic
sphere. The market sphere included 25 qualified life science companies. The companies were
classified according to the EU definition of small and medium enterprises (European Commission
2015). Companies that did not meet any SME definition were categorised as large-sized compa-
nies. The study included 5 large-sized companies, 2 medium-sized companies, 3 small-sized com-
panies and 15 micro-sized companies.
Sahlgrenska University Hospital is the largest university hospital in the region. University inno-
vation offices and platforms were established to support innovations generated by healthcare pro-
fessionals and researchers. Science parks and incubators were established to contribute to the
commercialisation of innovations. The BioVenture Hub is an innovative ecosystem integrated at
the AstraZeneca strategic research and development centre in Gothenburg, providing emerging
life science companies and academic groups unique opportunities to interact with each other and
with one of the largest incumbents on the market. The governance sphere included investors and
national actors, such as the Swedish Agency for Innovation Systems (Vinnova), the Swedish Patent
Office, the Swedish Medical Agency and the Ministry of Health and Social Affairs. Further, regional
Table 3. Metrics are used to rank the level of adoption AI healthcare technology innovations.
Metric Level of adoption Description
1 Pre-development Concepts and models are being developed.
3 Development Concepts or prototypes were further developed into pilot projects.
5 Take-off Technology was deployed in niche markets.
7 Acceleration Technology applications were adopted in established markets.
9 Stabilization Technologies had replaced existing technologies.
Table 4. Categorisation of participants from companies a, b, c, d, e and f.
Department or subdivision
Company size
Micro Small Medium Large
Market & business development c (1) d (1) b (1) a (1)
Computer science or IT — d (1) f (1) a (1)
Research & development e (1) — f (1) a (4)
Note: The number in parenthesis indicates the number of persons interviewed at the specific company.
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actors influencing the governance and market spheres included Business Region Göteborg (BRG), a
non-profit company working to develop regional industry and regional county offices and regional
bodies.
4.2. Functional assessment
This section describes the strengths (S) and weaknesses (W) of the system functions relating to AI
healthcare technology innovations.
4.2.1. Knowledge development and diffusion (F1)
A knowledge gap between decision-makers and AI experts was identified in a few of the medium- and
large-sized companies (W1). Not all decision-makers and managers had sufficient technological
knowledge to understand the potential impact AI innovations could have on the market or organ-
isations. In contrast, not all AI experts within the companies had the overall business perspective
needed to provide arguments for larger AI investments. The general market knowledge was
scarce among industrial actors, mainly due to a lack of experience with AI healthcare technology
innovations.
I think our greatest barrier is within our internal organization. We have lots of data, but to be honest, we don’t
know what we can do with it. (Business developer, company b, phase III)
Interview data and bibliometric analysis were used to assess scientific and technological knowl-
edge. There has been a slight increase in the number of scientific publications relating to AI healthcare
technology innovations, as illustrated in Figure 2; however, the absolute number of scientific publi-
cations related to life science and healthcare was low (W2). In comparison, the number of publications
related to AI technologies in all industrial sectors was analysed and researchers within West Sweden
representing all industrial sectors published approximately six times more articles, compared to what
would be expectedwhen compared to global TIS. The large number of publications is partly explained
by the intense collaboration between the local automotive industry and academia, which has resulted
Figure 1. Selection of key actors inspired by Larisch, Amer-Wåhlin, and Hidefjäll (2016). Boxes indicate study participants
included in phases I–III. Dotted boxes indicate actors who were contacted to identify participants for phases I–II.
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in a vast number of research projects related to electromobility. Hence, there was a broad technologi-
cal knowledge base due to the large number of activities in other sectors (S1).
To be frank, we as researchers will focus our research on where the funding is. Volvo and Geely invest huge
amounts of resources into advanced AI technologies for electromobility, whereas the local healthcare organiz-
ations support very few AI projects. (Senior AI researcher, phase I)
4.2.2. Legitimation (F2)
Qualitative and secondary data from published sources were analysed to assess the function
strength of legitimation (F2). AI experts expressed frustration regarding difficulties with the use of
health data, due to data liability and privacy concerns (W3). For example, re-using patient data col-
lected from previous clinical trials can be a key asset during development; however, previously col-
lected patient consent forms do not allow developers to use data originally intended for other
research projects, thus creating uncertainties concerning data ownership.
I wish that I had access to more patient data. The more data I have, the better prediction models I can develop.
(Senior developer, company a, phase III)
The length of time from application development to installation was analysed by assessing the
level of technology adoption. As described in Table 5, it was discovered that there was a low level
of adoption of healthcare technology innovations (W4). Only 9% of the service innovations were com-
mercially deployed and 73% were in pre-development. According to study participants, service inno-
vations were often delayed or postponed due to difficulties gaining internal and external acceptance
for the business model. For example, many experts were frustrated to present return on investment
projections and justify potential future revenue generation models. In contrast, approximately half of
the product innovations were commercially deployed and launched to paying customers and niche
Figure 2. The number of published scientific articles related to AI healthcare technology innovations in Sweden and in West
Sweden during 1998–2017.
Table 5. Level of commercially deployed AI healthcare technology innovations.
Commercially deployed AI healthcare technology innovations
Innovation type Pre-development Development Take-off Acceleration Stabilization
Product innovation 33% (2) 17% (1) 50% (3) — —
Service innovation 73% (16) 18% (4) 9% (2) — —
Note: Absolute numbers are outlined in parentheses.
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markets. Apart from being either physical product innovation or digital-virtual service innovation,
one of the main differences between product and service innovations was access to data. Thus,
the researchers hypothesise that the less control of data, the longer it will take to commercialise
AI healthcare technology innovations. As an example, decision support systems based on artificial
neural networks depend on access to healthcare databases, while product innovations (e.g. artificial
prosthesis) may only require data from individual patients. Hence, companies have more control
over the innovation process for physical product innovations compared to service innovations relat-
ing to services or processes where access to external healthcare databases is needed.
4.2.3. Resource mobilization (F3)
The function resource mobilisation (F3) was assessed with qualitative data and secondary data from
published sources. Infrastructure and accessibility to data are key to success for AI projects, the core
of which is the availability of relevant data to train and fine-tune AI functionality and accuracy.
Sweden is well recognised for its highly developed healthcare quality registries with a tremendous
amount of data for various medical procedures, such as the National Quality Register for hip fracture
patients, RIKSHÖFT. However, not all actors are allowed to use the data from healthcare databases,
and for non-academic actors in this study, the restrictions to use patient data from healthcare data-
bases and quality registries (W5) challenged the further development of AI healthcare technology
innovations. Two companies did not experience such difficulties; however, these companies were
founded by medical researchers from the academic sphere and could therefore access healthcare
databases.
The attractiveness of working with fast-moving sectors, such as electromobility, combined with
the perceived slow pace of development in the healthcare sector, has caused difficulties in attracting
AI-skilled talents in life science (W6).
Although I definitely value such projects, the pace of development in healthcare is way too slow for me. (Senior
AI researcher, phase I)
AI experts in academia experienced low financial resources (W7), which also was confirmed by ana-
lysing the total number of funding calls by the Swedish Agency for Innovation Systems (Vinnova).
Until the year 2017, there was one call related to the TIS; however, six calls were related to other
sectors. Further, many AI experts in medium- and large-sized companies were challenged by man-
agement to present return on investment for new projects, and the lack of evidence or uncertainties
often resulted in an unwillingness to invest. In contrast, micro- and small-sized companies often
attracted seed and venture capital for early-stage development projects. This was also confirmed
by one of the investors, who declared that local seed investors were willing to invest in new pro-
spects relating to AI technology innovations. However, the absolute number of projects, and
hence, the total amount of invested financial capital, was low.
We have decided to dedicate a full-time employee towards digitization technologies in order to identify new
business opportunities and to support our portfolio companies. (Senior investor, phase I)
4.2.4. Guidance of search (F4)
The function guidance of search (F4) was assessed with qualitative interview data and secondary
data from published sources from downstream market actors. Actors were chosen based on their
proximity to healthcare and patients, and hence, their knowledge and understanding of end-user
needs. For example, University Hospitals and Healthcare Innovation Platforms were included in
the analysis. Although there were a few articles from leading healthcare professionals relating to
the TIS, these were often not related to what is needed for AI technology innovations in healthcare.
The finding was confirmed by upstream market actors who perceived insufficient articulation by
leading healthcare professionals of the needs to improve healthcare with AI technology innovations
(W8). Interestingly, two small-sized companies did not experience a lack of guidance from leading
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healthcare professionals; however, the researchers concluded that these companies were founded
by renowned academic medical researchers with well-established networks in the healthcare
system; therefore, they did not need guidance in the same way the non-academic actors did.
We don’t actually know what healthcare organizations need. If they can guide us how AI can be utilized in their
daily operations, we would definitely be willing to invest. (Senior industry associate, phase I)
4.2.5. Entrepreneurial experimentation (F5)
The function entrepreneurial experimentation (F5) was assessed by the general promotion of inno-
vation in the area, the number of actors and different types of applications. The function was
strengthened by the strong culture of innovation in the region, such as well-established innovation
offices, science parks and incubators that were actively involved in various activities to catalyse
entrepreneurial activities and establish new companies based on university spin-offs. Further, the
number of new company entrants relating to the TIS has increased (S2) by approximately 25% since
2014. A few established medium- and large-sized life science companies had not yet initiated AI inno-
vation projects (W9), which had an overall negative effect on the function strength.
It has been difficult to move AI applications forward in the past. Recent high-profile events and the buzz around
AI has increased our possibilities for developing new applications. (Business developer, company b, phase III)
This study showed a variety of end-user applications (S3); 31% of the identified end-user appli-
cations were related to decision support, 19% to patient support, 16% to education, 13% to
medical device therapy, 12% to pharmaceutical development and 10% were related to diagnostic
applications.
4.2.6. Market formation (F6)
The function market formation (F6) was assessed based on qualitative data on actors’ strategies to
enhance market access and on the level of commercially deployed AI technology innovations. There
was a general view that collaborations between the technology-driven small-sized companies and
the medium- and large-sized companies would be help decrease the time to market.
We did not have the technology in house, so therefore we have recently acquired a start-up with very interesting
AI innovations. (IT manager, company f, phase III)
As described in Table 6, there were no AI technology innovations for healthcare applications com-
mercially deployed among medium- and large-sized companies (W10). In contrast, 31% of the AI
healthcare technology innovations developed by micro- and small-sized companies were deployed
commercially; however, these commercial AI innovations developed by micro- and small-sized compa-
nies were deployed to niche markets and did not yet generate significant revenues (W11). Hence, the
researchers concluded that overall, the market size for AI healthcare technology innovations at
the time of the study was small.
4.2.7. System-wide synergies (F7)
Many experts perceived difficulties initiating projects with actors represented by other spheres and
formal networks were sought to further develop knowledge and increase interdisciplinary collaboration
Table 6. Level of adoption of commercially deployed AI healthcare technology innovations according to study participants.
Company size
Commercially deployed AI healthcare technology innovations
Pre-development Development Take-off Acceleration Stabilization
Micro 50% (7) 21% (3) 29% (4) – –
Small – 50% (1) 50% (1) – –
Medium 100% (3) – – – –
Large 89% (8) 11% (1) – – –
Note: Absolute numbers are outlined in parentheses.
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(W12). A few of the medium- and large-sized companies with domain knowledge lacked the techno-
logical knowledge, and were thereby keen to establish collaboration with technology-driven small-
sized companies. In contrast, a majority (85%) of the small-sized companies in this study were
founded based on specific technology innovations, and they typically lacked domain knowledge.
Further, the so-called teacher exception rule regulating the intellectual property rights of academic
staff (Regeringskansliet 1949, 345) and the restrictive collaboration rules between industry and health-
care (W13) (SKL 2013) negatively influenced interdisciplinary collaboration and initiation of inno-
vation projects.
Just because I am knowledgeable in various fields of medicine, does not make me capable of developing inno-
vations relating to my field. We need to collaborate with the companies. (Healthcare professional, phase I)
Innovations based on machine learning technologies become more intelligent the more they are
being used, and thus can be improved once more data becomes available. Legal and regulatory
requirements relating to the management of the dynamic nature of such innovations were
unclear among many industrial actors. For example, it was unclear whether automatic upgrades
of software were allowed from a legal standpoint. This was also confirmed in the literature, and
according to the Swedish Institute for Standards (SIS), there is a lack of national and international
standards and regulations for AI healthcare technology innovations (W14).
4.2.8. Summary of the functional assessment
A summary of the functional assessment, including identified strengths and weaknesses of AI health-
care technology innovations from a life science industry perspective, is illustrated in Table 7. Two
system functions, knowledge development and diffusion (F1) and entrepreneurial experimentation
(F5), are assessed intermediate and can be regarded as cornerstones to further the TIS development
and performance. However, this study showed that the remaining four functions were weak and may
significantly restrict the development and innovation system performance.
4.3. Functional pattern
Many decision-makers expressed that the willingness to further investigate how AI technologies can
be utilised would increase if the need for the technology could be justified. Decision-makers urged
healthcare organisations to articulate their needs in relation to improving healthcare with AI tech-
nologies. Clearly communicated needs in combination with an increased legitimacy for AI inno-
vations will provide incentives for more actors to enter the field. Consequently, more resources
would be invested in new product development, resulting in a stronger knowledge base. Hence,
the guidance of search (F4) influences legitimation (F2) and entrepreneurial experimentation (F5)
and indirectly also impacts knowledge development and diffusion (F1) and resource mobilisation
(F3).
Only a fraction of data within internal company databases are analysed. Increased access and
structuring of such data would allow AI experts to experiment more. Furthermore, access to the
large multilevel datasets available in healthcare would empower AI experts to experiment and
potentially unlock novel insights. AI projects utilising internal and external data sources could
increase the understanding of potential business opportunities. Furthermore, it could catalyse the
alignment between regulatory requirements and technology developments, and moreover, the
establishment of standards. Hence, resource mobilisation (F3) influences experimentation (F5),
and indirectly influences knowledge development and diffusion (F1), market formation (F6) and
system-wide synergies (S7).
Based on the functional pattern, the researchers conclude that strengthening resource mobilis-
ation (F3) and guidance of search (F4) can start a cascade of activity with direct and indirect
influence on all functions (Figure 3).
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4.4. System-blocking mechanisms
As illustrated in Figure 4, addressing the function weakness insufficient articulation by healthcare pro-
fessionals of the needs to improve healthcare with AI technology innovations (W8), will have a direct
influence on the guidance of search (F4) and indirect influence on two other functions. Furthermore,
restrictions to use patient data from healthcare databases and quality registries (W5), difficulties to
attract AI-skilled talents to life science (W6) and low financial resources (W7) will influence resource
mobilisation (F3) and indirectly impact three other functions.
Thus, this analysis showed that some system-blocking mechanisms are more important to
address than others due to their direct and indirect influences on functions. Consequently, the
researchers conclude that addressing the function weaknesses of resource mobilisation (F3) and gui-
dance of search (F4) could have a significant impact on innovation system performance.
5. Discussion and conclusions
The purpose of this study was to assess the innovation system performance and identify the blocking
mechanisms for AI healthcare technology innovations related to the life science industry. Based on
Table 7. Identified system strengths and weaknesses.





base due to large amount of
activities in other sectors (S1).
Knowledge gap between decision-makers
and AI experts was identified in a few of the
medium- and large-sized companies (W1).
Absolute number of scientific publications




The number of new company
entrants relating to the TIS has
increased (S2).
Few established medium- and large-sized life
science companies had not yet initiated AI
innovation projects (W9).
Variety of end-user applications
(S3).
Weak F2 Legitimation Difficulties with the use of health data due to
data liability and privacy concerns (W3).
Low level of adoption of healthcare
technology innovations (W4).
F3 Resource mobilization Restrictions to use patient data from
healthcare databases and quality registries
(W5).
Difficulties to attract AI-skilled talents to life
science (W6).
Low financial resources (W7).
F4 Guidance of search Insufficient articulation by leading healthcare
professionals of the needs to improve
healthcare with AI technology innovations
(W8).
F6 Market formation No AI technology innovations for healthcare
applications commercially deployed
among medium- and large-sized
companies (W10).
Commercial AI innovations developed by
micro- and small-sized companies
deployed to niche markets and did not yet
generate significant revenues (W11).
F7 System-wide
synergies
Formal networks were sought to further
develop knowledge and increase
interdisciplinary collaborations (W12).
Restrictive collaboration rules between
industry and healthcare (W13).
Lack of national and international standards
and regulations for AI healthcare
technology innovations (W14).
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the analysis of functional dynamics and system-blocking mechanisms, the researchers conclude that
addressing the function weaknesses of resource mobilisation (F3) and guidance of search (F4) could
have a significant impact on innovation system performance.
5.1. Implications for policy interventions
As functions interact and influence each other, policy interventions and activities can be targeted
towards strengthening specific system-blocking mechanisms. This study shows that the innovation
system performance is primarily restricted by the systemweaknesses of limited resources and insuffi-
cient communication from leading healthcare professionals regarding their needs for improving
healthcare using AI technology innovations.
One approach to address the system-blocking mechanisms identified in this study would be to
establish a shared project portfolio platform, ideally funded by governmental bodies, to catalyse
interdisciplinary collaboration, in which actors from the academic, market and governance
spheres could work together on projects with clearly defined goals and objectives. An increased
number of such projects would provide opportunities for more actors to experiment and gain experi-
ence with AI technologies. For example, increasing access to health data from databases and the
Swedish quality registries would allow more actors to experiment with data. Such concrete projects
would also catalyse discussion on data liability and privacy concerns encouraging institutional actors
to align current regulations with recent technological developments.
Thus, to increase innovation system performance, policy interventions with the intention to
increase available resources and to formulate a vision and mission statements to improve healthcare
with AI healthcare technology innovations may be motivated.
5.2. Theoretical contributions
In other analyses of innovation systems (Hekkert and Negro 2009; Larisch, Amer-Wåhlin, and Hidefjäll
2016), knowledge development and diffusion (F1), legitimation (F2) and resource mobilisation (F3)
Figure 3. Interactions between system functions for AI healthcare technology innovations.
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have shown interdependencies by providing the initial conditions for entrepreneurial experimen-
tation (F5) and guidance of search (F4) in early phases of technological development. However, as
described in Figure 5, our analysis shows that knowledge development and diffusion (F1) and entre-
preneurial experimentation (F5) are interdependent and provide initial conditions for legitimation
(F2), resource mobilisation (F3), guidance of search (F4) and market formation (F6). More specifically,
the results reveal that innovation system performance is primarily restricted by the system weak-
nesses of limited resources and insufficient communication from leading healthcare professionals
regarding their needs for improving healthcare using AI technology innovations. Hence, despite
the limitations of using a single case study, the theoretical implications of our study show there
may be a correlation between knowledge development and diffusion (F1) and entrepreneurial
experimentation (F5) during the early phases of innovation system development. However, more
Figure 4. System-blocking mechanisms relating to the innovation system performance.
Figure 5. Interdependencies between system functions relating to the innovation system performance.
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research is needed to strengthen the empirical foundation, and therefore, we encourage more
research studies applying the TIS in a healthcare setting to better understand the adoption of
innovations.
5.3. Limitations
The researchers acknowledge the limitations of the present study, which should be considered when
drawing conclusions and building on the findings. This case study was based on the triangulation of
secondary data from published sources and interviews with 46 study participants, and may, there-
fore, not be indicative of the entire population. Thus, caution is needed whenmaking generalisations
based on this study’s findings. Another limitation of the study was the boundaries, which included
innovations relating to the life science industry, while innovations developed within healthcare
organisations were excluded. Hence, the authors call for further research of AI healthcare technology
innovations developed within and by healthcare organisations. The complexity of healthcare
systems and the rapid development of the innovation system from the time of data collection to
the publication of this report constitute a call for further studies to analyse the temporal develop-
ment of AI healthcare technology innovations.
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